HomeCompareASTGY vs JNJ

ASTGY vs JNJ: Dividend Comparison 2026

ASTGY yields 11.11% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ASTGY wins by $11.4K in total portfolio value
10 years
ASTGY
ASTGY
● Live price
11.11%
Share price
$18.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.7K
Annual income
$2,227.50
Full ASTGY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — ASTGY vs JNJ

📍 ASTGY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodASTGYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ASTGY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ASTGY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ASTGY
Annual income on $10K today (after 15% tax)
$944.44/yr
After 10yr DRIP, annual income (after tax)
$1,893.38/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $2,092.62/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ASTGY + JNJ for your $10,000?

ASTGY: 50%JNJ: 50%
100% JNJ50/50100% ASTGY
Portfolio after 10yr
$36.0K
Annual income
$3,458.45/yr
Blended yield
9.62%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ASTGY
No analyst data
Altman Z
1.9
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ASTGY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricASTGYJNJ
Forward yield11.11%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$41.7K$30.3K
Annual income after 10y$2,227.50$4,689.40
Total dividends collected$16.6K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ASTGY vs JNJ ($10,000, DRIP)

YearASTGY PortfolioASTGY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,811$1,111.11$10,592$272.30+$1.2KASTGY
2$13,864$1,226.49$11,289$357.73+$2.6KASTGY
3$16,180$1,345.52$12,123$472.89+$4.1KASTGY
4$18,781$1,467.56$13,141$629.86+$5.6KASTGY
5$21,687$1,591.96$14,408$846.81+$7.3KASTGY
6$24,923$1,718.07$16,021$1,151.60+$8.9KASTGY
7$28,513$1,845.28$18,122$1,588.22+$10.4KASTGY
8$32,482$1,972.96$20,930$2,228.20+$11.6KASTGY
9$36,856$2,100.55$24,792$3,191.91+$12.1KASTGY
10$41,664$2,227.50$30,274$4,689.40+$11.4KASTGY

ASTGY vs JNJ: Complete Analysis 2026

ASTGYStock

Hong Kong Aerospace Technology Group Limited, an investment holding company, provides electronics manufacturing services in the People's Republic of China, the United States, India, South Korea, Austria, Hong Kong, Brazil, Mexico, the United Kingdom, Germany, Vietnam, and Australia. The company provides design enhancement and verification; technical advice and engineering solutions; raw materials selection and procurement; quality control; logistic and delivery; and after-sale services for assembling and production of printed circuit board assemblies and fully-assembled electronic products for banking and finance, telecommunication, and smart device industries. Its fully-assembled electronic products include mobile phones, mobile point-of-sale, photovoltaic inverters, tablets, and street lamp controllers. It is also engaged in the sales of electronic products, satellite manufacturing, and satellite tracking and controlling services. Hong Kong Aerospace Technology Group Limited has a strategic cooperation agreement with the College of Engineering of City University of Hong Kong for the research and development of advanced satellite technology and related applications, such as communication systems, antenna technology, advanced materials, data processing, and energy management in Hong Kong. The company was formerly known as Eternity Technology Holdings Limited and changed its name to Hong Kong Aerospace Technology Group Limited in June 2021. The company was incorporated in 2003 and is based in Tseung Kwan O, Hong Kong. Hong Kong Aerospace Technology Group Limited is a subsidiary of Hong Kong Aerospace Technology Holdings Limited.

Full ASTGY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this ASTGY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ASTGY vs SCHDASTGY vs JEPIASTGY vs OASTGY vs KOASTGY vs MAINASTGY vs ABBVASTGY vs MRKASTGY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.